2025-03-12 18:01:54
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Tatva Chintan Pharma Chem Ltd Q4FY23 consolidated PAT increases QoQ to Rs. 16.95 crores
Posted On : 2023-05-06 10:37:21( TIMEZONE : IST )
Tatva Chintan Pharma Chem Ltd has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 125.356 crores during the period ended March 31, 2023 as compared to Rs. 121.684 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 16.954 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 11.623 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 7.65 for the period ended March 31, 2023 as compared to Rs. 5.24 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹125.356 crs | ₹121.684 crs |  3.02% |
| Net Profit | ₹16.954 crs | ₹11.623 crs | 45.87% |
| EPS | ₹7.65 | ₹5.24 | 45.99% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.125.356 crores during the period ended March 31, 2023 as compared to Rs.98.842 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.16.954 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.17.509 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.7.65 for the period ended March 31, 2023 as compared to Rs.7.90 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹125.356 crs | ₹98.842 crs | 26.82% |
| Net Profit | ₹16.954 crs | ₹17.509 crs |  -3.17% |
| EPS | ₹7.65 | ₹7.90 | -3.16% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.429.356 crores during the Financial Year ended March 31, 2023 as compared to Rs.442.664 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.45.487 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.95.874 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.20.52 for the Financial Year ended March 31, 2023 as compared to Rs.44.59 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹429.356 crs | ₹442.664 crs | -3.01% |
| Net Profit | ₹45.487 crs | ₹95.874 crs | -52.56% |
| EPS | ₹20.52 | ₹44.59 | -53.98% |
Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 1823.60 as compared to the previous close of Rs. 1835.95. The total number of shares traded during the day was 3463 in over 649 trades.
The stock hit an intraday high of Rs. 1845.00 and intraday low of 1784.10. The net turnover during the day was Rs. 6273425.00.
